BDTX

Black Diamond Therapeutics is a clinical-stage oncology company developing small-molecule inhibitors designed to target families of related cancer-driving mutations across multiple tumor types. Their lead program, silevertinib, is a brain-penetrant EGFR inhibitor currently in Phase 2 testing for lung cancer and planned for testing in brain tumors, with the ability to address over 50 different EGFR mutations including resistance mutations that emerge after other treatments. The company's approach uses a proprietary discovery platform to identify mutations that share similar structural changes, allowing a single drug to treat multiple genetic variants rather than just one specific mutation.

Pipeline

Catalyst Calendar